SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (OTC: SRNEQ, "Sorrento") today announces it has been awarded...
New panel will enable rapid, precise genetic profiling of patients with deadly diseaseNEW HAVEN, Conn., June 13, 2023 (GLOBE NEWSWIRE)...
NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a...
MINNEAPOLIS, June 13, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for...
White paper summarizes the research of leading inflammasome experts, Drs. Helen Bramlett, Juan Pablo de Rivero Vaccari, W. Dalton Dietrich,...
SAN DIEGO, June 13, 2023 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed...
Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients Paris, June 13, 2023. Sanofi...
Planegg/Martinsried, June 13, 2023. Medigene AG (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology platform company focusing on the discovery and...
Based on forthcoming completion of patient enrollment and duration of follow-up in Cohort 2 from the phase 2 trial in...
CAMBRIDGE, Mass. and NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage precision...
Lugano, Switzerland, June, 12, 2023 - Helsinn Group (“Helsinn”), a fully integrated global biopharma company with a track record of...
Company’s priority oncology clinical programs continue to advance toward key milestones Additional clinical trial site now open at University of...
Dr. Corinne Le Goff will highlight the breakthrough potential of IMNN-001 for the treatment of ovarian cancer during a panel...
BASKING RIDGE, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage...
AGOURA HILLS, Calif., June 12, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”),...
Prescription Drug User Fee Act (PDUFA) goal date of November 17, 2023Combined launch of vonoprazan for Erosive GERD and H....
MB-106 continues to demonstrate favorable safety and efficacy profile Overall response rate of 83% in cohort with durable responses observed;...
Myriad to support MD Anderson researchers studying metastatic renal cell carcinoma treatment selection and responseSALT LAKE CITY, June 12, 2023...
New proteomics data show that SP-3164 induces more degradation of cancer-promoting proteins than the standard-of-care agent lenalidomideHOUSTON, June 12, 2023...
Extended Phase 1 data reinforce the potential of NTLA-2002 to be a functional cure for people living with hereditary angioedema...